| Identification | Back Directory | [Name]
E3 Ligand-Linker Conjugate 10 | [CAS]
1957236-22-4 | [Synonyms]
E3 Ligand-Linker Conjugate 10
N-(14-Amino-3,6,9,12-tetraoxatetradecyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamide
Acetamide, N-(14-amino-3,6,9,12-tetraoxatetradec-1-yl)-2-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]oxy]- | [Molecular Formula]
C25H34N4O10 | [MDL Number]
MFCD31812591 | [MOL File]
1957236-22-4.mol | [Molecular Weight]
550.56 |
| Hazard Information | Back Directory | [Uses]
Thalidomide-O-amido-PEG4-C2-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology[1]. | [IC 50]
Cereblon | [References]
[1] James Bradner, et al. Methods to induce targeted protein degradation through bifunctional molecules. WO2016105518A1.
[2] Sato T, et al. Cereblon-Based Small-Molecule Compounds to Control Neural Stem Cell Proliferation in Regenerative Medicine.?Front Cell Dev Biol. 2021;9:629326. Published 2021 Mar 11. DOI:10.3389/fcell.2021.629326
[3] Nalawansha DA, et al. PROTACs: An Emerging Therapeutic Modality in Precision Medicine. Cell Chem Biol. 2020;27(8):998-985. DOI:10.7554/eLife.57277 |
|
|